

Supplementary Table 4. Serious adverse events in ATG- and placebo-treated subjects

| | <u>ATG</u> <u>Participants</u> (n=38) | <u>Events</u> | <u>Placebo</u> <u>Participants</u> (n=20) | <u>Events</u> |
|--------------------------------------|---|---------------|---|---------------|
| Participants with at least one SAE | 5 (13%) | 7 | 2 (10%) | 3 |
| Grade 1 | 0 | 0 | 0 | 0 |
| Grade 2 | 1 (3%) | 1 | 1 (5%) | 1 |
| Grade 3 | 2 (5%) | 3 | 1 (5%) | 2 |
| Grade 4 | 2 (5%) | 3 | 0 | 0 |
| | | | | |
| Depression | 1 (3%) | 2 | 1 (5%) | 1 |
| Diabetes mellitus inadequate control | 1 (3%) | 1 | 0 | 0 |
| Diabetic ketoacidosis | 0 | 0 | 1 (5%) | 1 |
| Hyperglycaemia | 1 (3%) | 1 | 0 | 0 |
| Hypoglycaemia | 1 (3%) | 1 | 0 | 0 |
| Ketosis | 1 (3%) | 1 | 0 | 0 |
| Salmonellosis | 1 (3%) | 1 | 0 | 0 |
| Suicidal ideation | 0 | 0 | 1 (5%) | 1 |